Table 1.
Yearly rates, rate ratios and reductions 2020–2021 vs. 2016–2019 in children < 18 years old
| Mean yearly rate | Yearly rate | Rate Ratio | Reduction | |
|---|---|---|---|---|
| Feb 2016-Jan 2020 | Feb 2020-Jan 2021 | |||
| Visitsa | ||||
| Overall clinic visits | 4852.1 ± 99.4 | 3804.1 | 0.784 (0.783 to 0.786) | 21.6% |
| Respiratory visits | 1938.3 ± 85.6 | 970.7 | 0.501 (0.499 to 0.503) | 49.9% |
| URI | 1459.4 ± 64.5 | 730.7 | 0.501 (0.499 to 0.504) | 49.9% |
| LRI | 158.3 ± 6.2 | 66.3 | 0.419 (0.413 to 0.426) | 58.1% |
| AOM | 281 ± 14.6 | 149.6 | 0.533 (0.528 to 0.539) | 46.7% |
| Asthma | 39.5 ± 2.2 | 24 | 0.608 (0.592 to 0.625) | 39.2% |
| AGE visits | 201.2 ± 11.3 | 106 | 0.527 (0.521 to 0.534) | 47.3% |
| Non-respiratory, non-AGE visits | 540.7 ± 19.9 | 381.5 | 0.706 (0.701 to 0.711) | 29.4% |
| UTI | 23.1 ± 0.9 | 18.9 | 0.818 (0.792 to 0.843) | 18.2% |
| Epilepsy | 15.8 ± 0.9 | 17.1 | 1.082 (1.046 to 1.119) | -8.2% |
| Trauma | 242.1 ± 8.9 | 193.9 | 0.801 (0.794 to 0.809) | 19.9% |
| SSTI | 57.5 ± 1.4 | 45 | 0.782 (0.766 to 0.798) | 21.8% |
| Prescriptionsa | ||||
| All respiratory prescriptions | 1577.1 ± 93.5 | 838.1 | 0.532 (0.53 to 0.535) | 46.8% |
| Respiratory antibiotics prescriptions | 766.4 ± 53.7 | 387.8 | 0.507 (0.504 to 0.51) | 49.3% |
| Amoxicillin/Amoxicillin clavulanate | 629 ± 44.3 | 316.6 | 0.504 (0.5 to 0.508) | 49.6% |
| Azithromycin | 126.1 ± 7.8 | 66.1 | 0.525 (0.517 to 0.533) | 47.5% |
| Ceftriaxone | 11.3 ± 1.6 | 5.1 | 0.455 (0.429 to 0.482) | 54.5% |
| Respiratory non-antibiotic prescriptions | 810.8 ± 40.6 | 450.3 | 0.556 (0.553 to 0.56) | 44.4% |
| Asthma inhalators and solutions | 270.7 ± 6.2 | 164.8 | 0.609 (0.603 to 0.615) | 39.1% |
| Throat relief and nasal congestion | 540.1 ± 37.1 | 285.5 | 0.53 (0.525 to 0.534) | 47.0% |
| All non-respiratory prescriptions | 118.6 ± 3.6 | 110.1 | 0.928 (0.916 to 0.94) | 7.2% |
| Non-respiratory antibiotics prescriptions | 56.1 ± 3 | 47.7 | 0.849 (0.832 to 0.866) | 15.1% |
| OFGC | 47.5 ± 3.2 | 41.7 | 0.876 (0.858 to 0.895) | 12.4% |
| TMP/SMX | 8.6 ± 0.8 | 6 | 0.697 (0.66 to 0.736) | 30.3% |
| Non-respiratory, non-antibiotics prescriptions | ||||
| Anti-epileptic | 62.5 ± 1 | 62.4 | 0.998 (0.981 to 1.016) | 0.2% |
URI upper respiratory tract infection, LRI lower respiratory tract infection, AOM acute otitis media, AGE acute gastroenteritis, UTI urinary tract infection, SSTI skin and soft tissue infection, OFGC oral first generation cephalosporins, TMP/SMX trimethoprim/sulfamethoxazole
aper 1,000 children